Christopher Richardson, MD
Dermatology · Rochester, NYNPI 1245573575
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,381 of the $36,735 with a category attached, or 99.0%. Merck accounts for 90.1% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $26,390, more than ten times the $17 reported in 2021. Among dermatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $1412.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$33K
- Biogen$3K
- Astrazeneca UK Limited$254
- Incyte Corporation$83
- Tactile Systems Technology Inc$17
Across 10 payments — averaging $16,276 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$121K
- Astrazeneca UK Limited$42K
What the payments were for
- Consulting fees$36,38199%
- Travel & lodging$1250%
- Food & beverage$2291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $33,101 |
| Biogen | 1 | $3,280 |
| Astrazeneca UK Limited | 2 | $254 |
| Incyte Corporation | 3 | $83 |
| Tactile Systems Technology Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$254
How this compares
$36,735 in reported general payments places this provider in the 90th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $72,859 |
| XolairOmalizumab | 11 | $45,940 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Rochester
- Lisa BeckRochester$755K
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.